VEGFA and myocardial infarction: Moreover, targeted intramyocardial delivery of VEGF‐C152S (an analog of human VEGF‐C156S) using albumin‐alginate microparticles dose‐dependently enhances cardiac lymphangiogenesis and inhibits pre‐collecting lymphatic vessel remodeling, which improves myocardial edema, inflammation, fibrosis, and dysfunction in rats after MI.16